JP2022513311A - カーゴ積載細胞外小胞 - Google Patents
カーゴ積載細胞外小胞 Download PDFInfo
- Publication number
- JP2022513311A JP2022513311A JP2021541011A JP2021541011A JP2022513311A JP 2022513311 A JP2022513311 A JP 2022513311A JP 2021541011 A JP2021541011 A JP 2021541011A JP 2021541011 A JP2021541011 A JP 2021541011A JP 2022513311 A JP2022513311 A JP 2022513311A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- rbcev
- aso
- extracellular vesicles
- cargo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023073005A JP2023099092A (ja) | 2018-09-21 | 2023-04-27 | カーゴ積載細胞外小胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862734303P | 2018-09-21 | 2018-09-21 | |
| US62/734,303 | 2018-09-21 | ||
| PCT/SG2018/050596 WO2020060479A1 (en) | 2018-09-21 | 2018-12-06 | Cargo loaded extracellular vesicles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023073005A Division JP2023099092A (ja) | 2018-09-21 | 2023-04-27 | カーゴ積載細胞外小胞 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022513311A true JP2022513311A (ja) | 2022-02-07 |
Family
ID=69887709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541011A Pending JP2022513311A (ja) | 2018-09-21 | 2018-12-06 | カーゴ積載細胞外小胞 |
| JP2023073005A Pending JP2023099092A (ja) | 2018-09-21 | 2023-04-27 | カーゴ積載細胞外小胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023073005A Pending JP2023099092A (ja) | 2018-09-21 | 2023-04-27 | カーゴ積載細胞外小胞 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20210355492A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2022513311A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020060479A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021145821A1 (en) | 2020-01-13 | 2021-07-22 | Carmine Therapeutics Pte. Ltd. | Nucleic acid loaded red blood cell extracellular vesicles |
| WO2021212066A2 (en) * | 2020-04-17 | 2021-10-21 | Ohio State Innovation Foundation | Rbc extracellular vesicles |
| CN117202894A (zh) * | 2021-03-31 | 2023-12-08 | 胭脂红治疗私人有限公司 | 负载至少两个不同核酸的细胞外囊泡 |
| IT202100027725A1 (it) * | 2021-10-28 | 2023-04-28 | Torino Politecnico | Metodo per l’ottenimento di popolazioni concentrate di vescicole extracellulari lavate del loro carico fisio-patologico |
| JP2024540165A (ja) * | 2021-11-01 | 2024-10-31 | シグマ-アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー | Crispr-casシステムのためのエレクトロポレーションエンハンサー |
| CN116763817A (zh) * | 2022-03-08 | 2023-09-19 | 中山大学 | 血液来源的样品在制备囊泡中的应用 |
| WO2023172208A1 (en) * | 2022-03-11 | 2023-09-14 | National University Of Singapore | Vesicle-based compositions and uses thereof |
| CN117126888A (zh) * | 2023-06-21 | 2023-11-28 | 安徽省立医院(中国科学技术大学附属第一医院) | 装载蛋白或多肽的细胞外囊泡递送平台及其应用 |
| IT202300026244A1 (it) * | 2023-12-07 | 2025-06-07 | Univerista Degli Studi Di Urbino Carlo Bo | Vescicole extracellulari derivate da globuli rossi caricate con molecole di carico per applicazioni terapeutiche e metodo di produzione delle stesse |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090274630A1 (en) * | 2008-05-01 | 2009-11-05 | National Health Research Institutes | Red blood cell-derived vesicles as a nanoparticle drug delivery system |
| JP2013515495A (ja) * | 2009-12-28 | 2013-05-09 | セントレ デ レセルカ エン サルト インテルナシオナル デ バルセロナ | プラスモジウム種に感染した網状赤血球由来のエキソソーム、それらの取得方法およびその用途 |
| WO2016187717A1 (en) * | 2015-05-26 | 2016-12-01 | Exerkine Corporation | Exosomes useful for genome editing |
| JP2017504312A (ja) * | 2013-12-12 | 2017-02-09 | ザ・ブロード・インスティテュート・インコーポレイテッド | ゲノム編集のためのCRISPR−Cas系及び組成物の送達、使用及び治療適用 |
| US20180067134A1 (en) * | 2016-09-08 | 2018-03-08 | UNIVERSITé LAVAL | Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing parkinson's disease |
| US20180161416A1 (en) * | 2015-06-03 | 2018-06-14 | Innovex Therapeutics, S.L. | Exosomes and their use as vaccine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017335084B2 (en) * | 2016-09-30 | 2023-06-29 | Ilias Biologics Inc. | Compositions containing protein loaded exosome and methods for preparing and delivering the same |
-
2018
- 2018-12-06 US US17/278,275 patent/US20210355492A1/en not_active Abandoned
- 2018-12-06 WO PCT/SG2018/050596 patent/WO2020060479A1/en not_active Ceased
- 2018-12-06 JP JP2021541011A patent/JP2022513311A/ja active Pending
-
2023
- 2023-04-27 JP JP2023073005A patent/JP2023099092A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090274630A1 (en) * | 2008-05-01 | 2009-11-05 | National Health Research Institutes | Red blood cell-derived vesicles as a nanoparticle drug delivery system |
| JP2013515495A (ja) * | 2009-12-28 | 2013-05-09 | セントレ デ レセルカ エン サルト インテルナシオナル デ バルセロナ | プラスモジウム種に感染した網状赤血球由来のエキソソーム、それらの取得方法およびその用途 |
| JP2017504312A (ja) * | 2013-12-12 | 2017-02-09 | ザ・ブロード・インスティテュート・インコーポレイテッド | ゲノム編集のためのCRISPR−Cas系及び組成物の送達、使用及び治療適用 |
| WO2016187717A1 (en) * | 2015-05-26 | 2016-12-01 | Exerkine Corporation | Exosomes useful for genome editing |
| US20180161416A1 (en) * | 2015-06-03 | 2018-06-14 | Innovex Therapeutics, S.L. | Exosomes and their use as vaccine |
| US20180067134A1 (en) * | 2016-09-08 | 2018-03-08 | UNIVERSITé LAVAL | Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing parkinson's disease |
Non-Patent Citations (3)
| Title |
|---|
| DANESH A, ET AL.: "Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting", BLOOD, vol. 123(5), JPN6022045337, 30 January 2014 (2014-01-30), pages 687 - 696, ISSN: 0005121105 * |
| GANGADARAN P, ET AL.: "In vivo Non-invasive Imaging of Radio-Labeled Exosome-Mimetics Derived From Red Blood Cells in Mice", FRONT PHARMACOL, vol. 9, JPN6022045338, 30 July 2018 (2018-07-30), pages 817, ISSN: 0004907740 * |
| PRUDENT M, ET AL.: "Differences between calcium-stimulated and storage-induced erythrocyte-derived microvesicles", TRANSFUS APHER SCI, vol. 53(2), JPN6022045336, October 2015 (2015-10-01), pages 153 - 158, ISSN: 0005295584 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020060479A1 (en) | 2020-03-26 |
| JP2023099092A (ja) | 2023-07-11 |
| US20210355492A1 (en) | 2021-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023099092A (ja) | カーゴ積載細胞外小胞 | |
| JP7343920B2 (ja) | マトリックス結合ナノベシクルおよびその使用 | |
| Usman et al. | Efficient RNA drug delivery using red blood cell extracellular vesicles | |
| US10709797B2 (en) | Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy | |
| EP3563859B1 (en) | Cardiosphere-derived exosomes for tissue regeneration | |
| US11970718B2 (en) | Nucleic acid loaded extracellular vesicles | |
| AU2019243179B2 (en) | Use of exosomes for targeted delivery of therapeutic agents | |
| JP7602246B2 (ja) | エキソソームを用いる腫瘍抑制因子の治療的調整法 | |
| CN108175759A (zh) | 一种抗肿瘤靶向给药系统及其制备方法与应用 | |
| US20210369858A1 (en) | Use of exosomes for targeted delivery of therapeutic agents | |
| JP7599698B2 (ja) | エキソソームを用いたがん遺伝子に対する治療的な標的指向化の方法 | |
| Tan et al. | Skimmed bovine milk-derived extracellular vesicles isolated via “salting-out”: Characterizations and potential functions as nanocarriers | |
| WO2016196822A1 (en) | Urodele exosomes as therapeutic agents | |
| US20260102512A1 (en) | Compositions and methods related to megakaryocyte-derived extracellular vesicles for fanconi anemia | |
| CN108175861A (zh) | 一种抗肿瘤小核酸药物的递送系统及其应用 | |
| WO2024196875A1 (en) | Compositions and methods useful for the treatment and management of obesity associated metabolic dysfunction | |
| AU2022386233A1 (en) | Biomarkers of megakaryocyte-derived extracellular vesicles | |
| CN117580949A (zh) | 工程化的胞外囊泡 | |
| Pottash | Strategies for small RNA loading into extracellular vesicles | |
| Phan | Cardioprotective Extracellular Vesicles Derived-Micrornas: Sorting Mechanisms and Functions | |
| HK40006800A (en) | Isolation of extracellular vesicles from red blood cells for gene therapy | |
| HK1260123A1 (en) | Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20210519 |
|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20210616 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211202 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211202 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221028 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230427 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230802 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240201 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240402 |